Ashton Thomas Securities’s Bristol-Myers Squibb BMY Stock Holding History

Ashton Thomas Securities’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,644	Closed	-$74.1K	–	305
2025 Q3	$74.1K	Buy	+1,644	New	+$76.8K	0.01%	342
2025 Q2	–	Sell	-7,001	Closed	-$427K	–	286
2025 Q1	$427K	Buy	+7,001	New	+$408K	0.12%	168
2024 Q4	–	Sell	-1,689	Closed	-$87.4K	–	360
2024 Q3	$87.4K	Buy	+1,689	New	+$79.2K	0.02%	343

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ashton Thomas Securities's BMY Position: Q4 2025 in Review

Ashton Thomas Securities sold out of Bristol-Myers Squibb (BMY) in Q4 2025, closing a stake of 1,644 shares — an estimated $74.1K sold.

Ashton Thomas Securities first reported a position in BMY in Q3 2024 and held it in 3 quarters. The position peaked at $427K in Q1 2025. 2,454 funds tracked by Wall St. Rank hold BMY as of Q4 2025.

Ashton Thomas Securities reported no remaining Bristol-Myers Squibb position as of Q4 2025 after selling out during the quarter.
Ashton Thomas Securities sold 1,644 Bristol-Myers Squibb shares in Q4 2025, an estimated $74.1K.
Ashton Thomas Securities first reported a position in Bristol-Myers Squibb in Q3 2024 and held it in 3 quarters.
Ashton Thomas Securities's Bristol-Myers Squibb position peaked at $427K in Q1 2025.
2,454 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2025.

Based on Ashton Thomas Securities's 13F filing for Q4 2025, filed 2 Feb 2026.